John Libbey Eurotext

Journal de Pharmacie Clinique


Is obesity a risk factor for docetaxel toxiciy? A pilot study Volume 32, issue 3, Septembre 2013

Département de pharmacie, Institut Jean Godinot, CLCC de Reims, France, Département d’oncologie médicale, Institut Jean Godinot, CLCC de Reims, France
  • Key words: docetaxel, obesity, tolerance, toxicity
  • DOI : 10.1684/jpc.2013.0256
  • Page(s) : 161-6
  • Published in: 2013

Few data are available in the literature regarding dosage adjustment of chemotherapy in obese patients. The aim of this work was to compare the tolerance of docetaxel in patients treated for breast cancer in the adjuvant setting according to their BMI was greater than 30 kg/m 2 or not. The assessed criteria were related to the toxicity of docetaxel: neutropenia, hand-foot syndrome, mucositis, and neuropathy. Eleven patients (64.7%) of the BMI group > 30 showed toxicity versus 7 patients (21.2%) in the other group (p = 0.013). Clinical studies are required to identify the different mechanisms of toxicity of docetaxel involved in obese patients and the measures to be taken to achieve the best efficacy/toxicity balance outcome for the patient.